How Are Hedge Funds Feeling About Fibrocell Science Inc (FCS)?

Now, key hedge funds were leading the bulls’ herd. QVT Financial assembled the biggest position in Fibrocell Science Inc (NASDAQ:FCS), while Akanthos Capital also made an $0.2 million investment in the stock during the third quarter.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Fibrocell Science Inc (NASDAQ:FCS) but similarly valued. These stocks are TriplePoint Venture Growth BDC Corp (NYSE:TPVG), TrovaGene Inc (NASDAQ:TROV), Tobira Therapeutics Inc (NASDAQ:TBRA), and Nathan’s Famous, Inc. (NASDAQ:NATH). All of these stocks’ market caps match FCSC’s market cap.

As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $17 million. That figure was $16 million in FCSC’s case. Nathan’s Famous, Inc. (NASDAQ:NATH) is the most popular stock in this table, while TriplePoint Venture Growth BDC Corp (NYSE:TPVG) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks, Fibrocell Science Inc (NASDAQ:FCS) is even less popular than TPVG. Considering that hedge funds aren’t fond of this stock in relation to other companies analyzed in this article, it may be a good idea to analyze it in detail and understand why the smart money isn’t behind this stock. This isn’t necessarily bad news. Although it is possible that hedge funds may think the stock is overpriced and view the stock as a short candidate, they may not be very familiar with the bullish thesis. In either case more research is warranted.